Isosulfan Blue

Quick links

Choose a section

Quick links to important sections

Advertisements

Isosulfan Blue

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Isosulfan Blue

Isosulfan Blue is a synthetic dye classified as a diagnostic agent primarily used in surgical oncology. It is most recognized under the trade name Lymphazurin, and is supplied as a sterile, single-use solution for injection. The active ingredient is Isosulfan Blue. As an injectable agent administered in a clinical setting, it is always an Rx (prescription-only) medicine.

Property Description
Active ingredient Isosulfan Blue
Form Sterile solution for injection
Pharmacological class Diagnostic agent (Lymphatic mapping agent)
Common use Sentinel lymph node mapping in cancer surgery
Origin Synthetic dye

The principal use of Isosulfan Blue is to visibly stain and map the lymphatic system during certain cancer operations, a procedure known as sentinel lymph node biopsy (SLNB). When injected near the site of a tumor, the dye is quickly absorbed by the lymphatic channels and flows to the sentinel lymph node—the first node to which cancer cells are likely to spread.

Isosulfan Blue provides visual contrast during surgery for staging several types of cancer, particularly breast cancer and melanoma. This is what differentiates it from general dyes; it is specifically designed to be taken up by the lymphatic vessels for this precise purpose. As a coloring agent, it is used for identifying sentinel lymph nodes in breast cancer surgery, contributing to the staging process.

Its reliable tracing capability has established it as a diagnostic tool in oncology. Functionally, it acts as a temporary coloring agent used to visualize lymphatic drainage patterns.

In summary, Isosulfan Blue is a diagnostic tool that provides surgeons with the visual guidance necessary to perform sentinel lymph node biopsies.

Advertisements

What side effects are possible with Isosulfan Blue?

Possible side effects and safety information

The official regulatory documentation for Isosulfan Blue (Lymphazurin) structures the safety profile around the potential for allergic reactions and constraints related to the dye's physical properties.

Key Adverse Reaction Scope

Category Documented Characteristics
Immune System Serious, life-threatening anaphylactic reactions are explicitly documented, including manifestations such as respiratory distress and shock. The overall incidence of hypersensitivity reactions is approximately 2% according to FDA labeling.
Skin & Tissue Adverse reactions include local reactions, urticaria, pruritus, and angioedema. The expected, inherent effect of the dye is transient or long-term blue coloration (tattooing) of the skin and subcutaneous tissues.

Safety Considerations and Limitations

The most significant safety consideration is the risk of life-threatening anaphylactic reactions, requiring patient monitoring for at least 60 minutes post-administration. Patients identified as being at higher risk for these reactions include those with a history of bronchial asthma, allergies, or prior reactions to triphenylmethane dyes.

Isosulfan Blue is also known to interfere with certain diagnostic equipment. It can cause falsely low readings when using pulse oximetry to measure oxygen saturation in the peripheral blood, with this interference being maximal at approximately 30 minutes after injection. It may also lead to falsely elevated methemoglobin readings. Safety and effectiveness are not established in pediatric patients, and caution is advised for nursing mothers, according to official prescribing information.

Advertisements

Overdose and Emergency Response

The official regulatory documents indicate that overdosage levels for Isosulfan Blue injection have not been formally identified in prescribing information. Management guidance is therefore strictly focused on the most severe, life-threatening risk associated with its administration: the potential for anaphylactic reactions.

Seek immediate medical attention if any sign of a severe systemic reaction occurs. The reaction may present as respiratory distress, shock, angioedema, or widespread pruritus. The official labeling mandates that trained personnel must be available to administer emergency care, including resuscitation, immediately upon the recognition of a life-threatening event.

Continuous monitoring of the patient for a period of at least 60 minutes following the injection is required. A crucial consideration in emergency settings is that the dye interferes with standard monitoring equipment: it can cause falsely low readings on pulse oximetry. To accurately verify the patient’s oxygen status, alternative methods such as Arterial Blood Gas (ABG) analysis or co-oximetry may be necessary, as documented by regulators.

There is no specific antidote listed in the regulatory documents for the treatment of severe reactions or overdose. Patients with a known history of bronchial asthma or allergies are noted to have an increased likelihood of experiencing these severe outcomes.

Advertisements

Therapeutic Uses of Isosulfan Blue

Isosulfan Blue is applied as a diagnostic agent that supports surgical assessment and management across oncology and lymphatic conditions.

Its application involves therapeutic areas where the assessment of lymph node involvement by primary or secondary neoplasm (cancer) is needed. This includes conditions where staging of tumors like breast cancer and melanoma is commonly required, as well as the assessment of primary and secondary lymphedema of the extremities, and persistent fluid conditions like chyluria, chylous ascites, or chylothorax.

The dye plays a role in clinical management by assisting with the surgical approach during procedures like sentinel lymph node biopsy. This supportive role contributes to the surgical strategy and may be relevant for supporting patients experiencing symptoms related to long-term physical complications through more precise mapping.

“The agent is commonly used to support decision-making in clinical settings that involve acute or unstable symptom patterns related to lymphatic drainage.”

In complex lymphatic disorders, the dye is applied across domains where additional symptomatic support is needed. Its application may assist with maintaining functional stability in situations where patients experience disruptive symptom manifestations and discomfort by providing visual clarity for interventions.


Quick Fact: Support for Surgical Management

The dye supports surgical strategies aimed at minimizing tissue removal, which contributes to patient comfort during periods of heightened symptoms by facilitating less invasive surgical choices and assisting with maintaining functional stability.

Regulatory References

  1. NIH DailyMed service
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

Isosulfan Blue's eligibility profile is strictly defined by government regulatory documents, outlining populations that are excluded, restricted, or where data on safety is not established.

Populations Excluded from Use (Contraindications)

Individuals must not use Isosulfan Blue if they have a known hypersensitivity or allergy to the injection itself or to triphenylmethane or related chemical compounds. This represents an absolute exclusion based on the risk of severe reactions.

Use Restrictions and Data Limitations

Population Group Regulatory Status Practical Implication
Pediatric Patients (Children) Safety and effectiveness not established. Officially excluded from documented use due to insufficient data.
Pregnant Women Pregnancy Category C (FDA); use is conditional. Should only be administered if clearly needed, due to unknown potential for fetal harm.
Nursing Mothers Use requires caution. Caution is advised due to the lack of information on whether the drug is excreted in human milk.

Eligibility is also restricted for patients with a history of asthma, allergies, or previous drug reactions, as these individuals may have a higher likelihood of experiencing anaphylactic reactions.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Isosulfan Blue is primarily defined by the absence of systemic drug interactions, with restrictions documented for physical incompatibility during administration and interference with medical monitoring products.

Interaction Scope

Medicinal product categories with documented interactions:

  • Local anesthetics
  • Diagnostic monitoring equipment

Specific interacting constraints and rules:

  • Administration Timing/Physical Incompatibility: The regulatory label specifies that the dye must not be admixed with local anesthetics, such as lidocaine, in the same syringe. This prohibition is due to immediate precipitation of the drug complex that occurs upon co-admixture.
  • Diagnostic Product Interference: The dye interferes with certain patient measurements, leading to inaccurate results. Co-administration causes falsely low readings in peripheral blood pulse oximetry. It may also result in falsely elevated readings of methemoglobin when measured by arterial blood gas analyzers. The interference effect on oxygen saturation is maximal at approximately 30 minutes and minimal generally by four hours after administration.

Interaction Classifications

Systemic Drug-Drug Interactions:

  • No systemic pharmacokinetic or pharmacodynamic interactions between Isosulfan Blue and other medicinal products have been identified in official labeling.

Resulting interaction structure: The official regulatory interaction profile is defined by an absence of documented systemic drug-drug interactions, meaning no CYP-mediated or transporter-based interactions are listed. The key regulatory constraints involve mandatory procedural rules for administration to prevent physical incompatibility with local anesthetics. This profile is further structured by documented optical interference with certain diagnostic products used to monitor patient status in the clinical setting.

Advertisements

Mechanism of Action

Isosulfan Blue is a triarylmethane dye whose primary action is defined by its physical properties and distribution within the biological environment. The dye acts as a passive tracer within the lymphatic system to enable visualization of lymphatic movement.


Lymphatic Tracing and Localization

Following interstitial administration, Isosulfan Blue undergoes preferential and rapid uptake by lymphatic capillaries. This process is not mediated by typical receptor or enzyme signaling but by the dye's physicochemical properties, including molecular size and charge. The uptake mechanism culminates in the accumulation of the dye within the lymphatic lumen, resulting in localized tissue staining.


Selective Lymphatic Transport

The chemical structure of the dye promotes its efficient absorption and transport through the lymphatic vasculature with limited diffusion into the systemic circulation. This selective transport establishes a localized contrast within the lymphatic system, delineating the distribution of drainage pathways, which ultimately results in the accumulation of the dye in regional lymph nodes.

Advertisements

Dosage and Administration Information

Isosulfan Blue is administered as a single-event subcutaneous injection, serving as a diagnostic adjunct in specific medical procedures. The administration is strictly limited to controlled clinical environments and is not part of any long-term or scheduled regimen. The dye is supplied as a sterile, ready-to-use 1% aqueous solution (10 mg/ mL) that requires no prior reconstitution.

Administration Protocol

The protocol is defined by a precise volume and a total dose limit per procedure. The standard regimen involves injecting 0.5 mL (5 mg) of the solution at designated sites, typically into the interdigital spaces of an extremity. The maximum total dose administered during any single study must not exceed 3 mL (30 mg).

A mandatory administration constraint requires that the dye must not be mixed with local anesthetics (such as lidocaine) in the same syringe, as this action immediately results in precipitation of the drug. If both agents are required for the procedure, they must be administered separately.

Population Use and Handling

The safety and effectiveness of Isosulfan Blue have not been established for use in pediatric patients (those under 18 years of age). Furthermore, there is no established guidance for dose adjustment in patients with renal or hepatic impairment. Any unused portion of the solution from the single-dose vial must be discarded following the completion of the procedure.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Isosulfan Blue


Evidence for Use in Sentinel Lymph Node Mapping for Breast Cancer

A significant portion of the research on Isosulfan Blue has focused on its use as a diagnostic agent during the surgical staging of breast cancer. This research has involved extensive systematic reviews and meta-analyses that consolidate data from multiple Randomized Controlled Trials (RCTs), exploring diagnostic metrics that were measured in studies related to cancer staging. These studies primarily explored the dye's role in the process used by surgeons to locate the sentinel lymph node—the first node to which cancer cells may be carried.

The main focus of these trials was on technical metrics, such as the success rate of sentinel lymph node identification and diagnostic accuracy for staging the cancer. Research so far indicates that studies consistently reported patterns of successful visualization and localization measurements during the procedure. Reported outcomes consistently centered on short-term diagnostic metrics related to successful surgical staging.


Evidence for Use in Sentinel Lymph Node Mapping for Melanoma

Research has also explored the use of Isosulfan Blue in a similar diagnostic capacity for the surgical staging of melanoma. This evidence base is built mainly on observational studies and comparative diagnostic studies, rather than RCTs focusing solely on this dye. These studies monitored the dye's technical utility and identification success rate when applied during surgery for primary cutaneous melanoma. Data show patterns related to visualization measurements, with research providing insight into short-term changes observed during the operation.


Key Uncertainties and Research Gaps

Isosulfan Blue research consistently focuses on technical or diagnostic endpoints, which means there is a lack of data exploring long-term consequences or patient-reported outcomes describing perceived discomfort. For the melanoma indication, comparative evidence is limited as studies often group Isosulfan Blue with other blue dyes, meaning specific findings are uncertain. Additionally, research is limited in specialized areas like the assessment of lymphedema, where studies rely on small-scale case series and observational reports, and certainty remains low regarding the consistency of technical success across diverse patient physiologies.

Key Studies & References Isosulfan Blue Injection, USP (Lymphazurin)—Official Labeling (NIH DailyMed)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Isosulfan Blue (FAQ)


Q: How quickly does Isosulfan Blue start to work after it is given?

Official studies on the dye's absorption show that approximately 69% of the dose is absorbed from the injection site within one hour. The dye's primary function—providing visualization for the surgeon—relies on this process of rapid uptake and transport through the lymphatic system.


Q: Can Isosulfan Blue cause my urine to change color?

Yes, official product information indicates that Isosulfan Blue may cause your urine to temporarily turn blue or blue-green. This is an expected effect related to how the dye is processed naturally by the body.


Q: What happens if I forget to mention a medicine I take before receiving Isosulfan Blue?

Official labeling states that systemic (body-wide) interactions between Isosulfan Blue and other medicinal products have not been identified. It is standard procedure to inform healthcare providers of all medicines used prior to the administration of any diagnostic agent.


Q: Do older adults react differently to Isosulfan Blue?

According to official prescribing information, there is no specific information available on the relationship of age to the effects of the injection in geriatric (older) patients.


Q: What is the difference between Isosulfan Blue and Methylene Blue?

Research notes that these are two different types of chemical dyes. Isosulfan Blue is classified as a triphenylmethane dye, while Methylene Blue is classified as a thiazine dye. This difference in chemical structure results in variations in how each dye is concentrated by the body's lymphatic system.


Q: Does Isosulfan Blue have a black box warning?

No, the official prescribing information does not contain a Boxed Warning (the term for a black box warning). However, the label does include a prominent Warning section to highlight the known risk of severe, life-threatening anaphylactic reactions.


Q: Is there a generic version of Isosulfan Blue available?

Yes, generic versions of Isosulfan Blue Injection are available. The FDA has evaluated these generic products to be comparable to the brand-name product, which is often known as Lymphazurin.


Q: Has Isosulfan Blue been linked to any long-term side effects?

The only long-term effect documented in the official safety profile is the possibility of long-term blue coloration (tattooing) of the skin and subcutaneous tissues at the injection site. Research notes that there is a current lack of data exploring other long-term consequences.


Q: Can I receive Isosulfan Blue if I have kidney problems?

Official regulatory guidelines state that there is no established guidance for dose adjustment for patients with existing kidney (renal) or liver (hepatic) impairment. In the absence of specific dosing guidance, official procedures require that healthcare providers are aware of all pre-existing conditions prior to administration.


Q: Is Isosulfan Blue mentioned in official cancer treatment guidelines?

Official information describes the dye's function as a temporary coloring agent that helps visualize lymphatic drainage patterns. This function supports its use in sentinel lymph node biopsy (SLNB), which is a procedure used in surgical cancer staging protocols.


Q: What is the general success rate mentioned in research for procedures involving Isosulfan Blue?

Clinical research has reported various success rates for using the dye during sentinel lymph node detection. Some initial studies indicated a successful visualization rate of up to 93% using the blue dye alone, though combined methods may show higher rates.


Q: If Isosulfan Blue causes a reaction, what is the official advice about next steps?

Due to the risk of severe reactions, official warnings emphasize that emergency facilities and competent personnel should be available. Official warnings also state that healthcare teams are required to monitor patients for 30 to 60 minutes after administration.


Q: Is Isosulfan Blue always necessary for a sentinel lymph node biopsy?

Official labeling describes the dye as an adjunct (an assisting agent) to lymphography. It is one of several agents, including radioactive tracers, that may be used during the sentinel lymph node biopsy procedure.


Q: Is Isosulfan Blue ever used outside of cancer-related procedures?

Yes, official information states that the drug is also indicated as an adjunct to lymphography for conditions such as primary and secondary lymphedema of the extremities.


Q: Are there certain medical conditions that would make someone ineligible for Isosulfan Blue?

Individuals with a known hypersensitivity or allergy to the injection or to related compounds (triphenylmethane) are generally restricted from use. Caution is also advised for patients with a history of bronchial asthma, allergies, or previous drug reactions.


Q: Does Isosulfan Blue contain iodine?

Isosulfan Blue is chemically classified as a triphenylmethane dye. Its chemical structure, as described in official labeling, does not include iodine.


Q: If someone is allergic to other dyes, can they still receive Isosulfan Blue?

The official contraindication is specific to allergies to Isosulfan Blue or related triphenylmethane compounds. Official labeling does not list allergies to other, unrelated dye types (such as iodine-based contrast agents) as a direct contraindication.


Q: Why do doctors prefer Isosulfan Blue over other color dyes in some cases?

Research indicates that the dye's specific chemical structure gives it optimal characteristics for being selectively taken up and concentrated by the lymphatic system. This selectivity helps provide reliable visualization for surgeons during a procedure.


Q: How does Isosulfan Blue compare to technetium sulfur colloid in sentinel node mapping?

Isosulfan Blue is a visible blue dye, while technetium sulfur colloid is a radioactive tracer. Research comparing the two agents often suggests that using a combined approach (dye and tracer) yields the highest rate of successful sentinel lymph node identification.

Advertisements

How should Isosulfan Blue be stored and disposed of?

Isosulfan Blue Injection must be stored at Controlled Room Temperature, which is strictly maintained between 20^circC and 25^circC (68^circF and 77^circF). Official labeling requires the product to be protected from excessive heat. The container must be kept out of reach of children.


Disposal Instructions

Because Isosulfan Blue is supplied in a single-dose vial, regulatory instructions mandate the discarding of any unused portion immediately after administration. Disposal of the pharmaceutical waste must adhere to local, regional, national, and international environmental control regulations. Specifically, the product should not be discharged into sewers or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isosulfan Blue found in:

A-Z Index: